Form 8-K - Current report:
SEC Accession No. 0001493152-22-015982
Filing Date
2022-06-06
Accepted
2022-06-06 16:03:35
Documents
21
Period of Report
2022-06-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39597
2 ex99-1.htm EX-99.1 10505
3 ex99-1_001.jpg GRAPHIC 246127
4 ex99-1_002.jpg GRAPHIC 334117
5 ex99-1_003.jpg GRAPHIC 366537
6 ex99-1_004.jpg GRAPHIC 336074
7 ex99-1_005.jpg GRAPHIC 294871
8 ex99-1_006.jpg GRAPHIC 336702
9 ex99-1_007.jpg GRAPHIC 201278
10 ex99-1_008.jpg GRAPHIC 306406
  Complete submission text file 0001493152-22-015982.txt   3557555

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE lpcn-20220606.xsd EX-101.SCH 2959
12 XBRL LABEL FILE lpcn-20220606_lab.xml EX-101.LAB 34240
13 XBRL PRESENTATION FILE lpcn-20220606_pre.xml EX-101.PRE 22359
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3605
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 22998060
SIC: 2834 Pharmaceutical Preparations